Amgen Stock Surges on Dazodalibep Trial Success

Amgen stock rose by 4.34% on September 22, 2026, closing at $410.24 on the Nasdaq. This increase followed positive Phase 3 trial data for dazodalibep in Sjogren's disease. The OASIZ 301 study met its primary endpoint, showing promise for Amgen's pipeline.

Jefferies raised its price target for dazodalibep to $4.5 billion from $1 billion after the data was released. However, another study must report before Amgen can submit a regulatory filing. The expected OASIZ-303 data are scheduled for the fourth quarter of 2026.

Amgen's quarterly earnings per share were $6.29 and revenue was $10.05 billion for the quarter ended June 30, 2026. EPS exceeded the consensus estimate by $0.67 and revenue was 9.5% above the comparable quarter's level.